- Home
- SGHT
SGHT
Sight Sciences Inc.
as 01-21-2025 4:00pm EST
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 304.4M | IPO Year: | 2021 |
| Target Price: | $5.10 | AVG Volume (30 days): | 260.5K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.67 - $8.45 | Next Earning Date: | 03-06-2025 |
| Revenue: | $79,543,000 | Revenue Growth: | -3.99% |
| Revenue Growth (this year): | 2.13% | Revenue Growth (next year): | 7.99% |
Stock Insider Trading Activity of Sight Sciences Inc. (SGHT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HAYDEN JEREMY B. | SGHT | Chief Legal Officer | Jan 17 '25 | Sell | $2.78 | 6,922 | $19,250.08 | 145,091 | |
| Badawi Paul | SGHT | President and CEO | Jan 16 '25 | Sell | $2.92 | 24,819 | $72,570.76 | 5,676,331 | |
| HAYDEN JEREMY B. | SGHT | Chief Legal Officer | Jan 8 '25 | Sell | $3.26 | 1,810 | $5,898.79 | 145,091 | |
| HAYDEN JEREMY B. | SGHT | Chief Legal Officer | Jan 3 '25 | Sell | $3.52 | 4,864 | $17,131.01 | 145,091 | |
| Bauerlein Alison | SGHT | Chief Financial Officer | Jan 3 '25 | Sell | $3.52 | 10,102 | $35,579.24 | 382,453 | |
| Raheja Manohar K. | SGHT | EVP, Research & Development | Dec 6 '24 | Buy | $3.85 | 5,000 | $19,250.00 | 111,000 | |
| Raheja Manohar K. | SGHT | EVP, Research & Development | Dec 3 '24 | Buy | $3.89 | 3,376 | $13,132.64 | 111,000 | |
| Raheja Manohar K. | SGHT | EVP, Research & Development | Nov 29 '24 | Buy | $3.99 | 4,624 | $18,440.51 | 111,000 | |
| Encrantz Staffan | SGHT | Director10% Owner | Nov 21 '24 | Buy | $3.73 | 551,802 | $2,058,221.46 | 4,573,920 | |
| Encrantz Staffan | SGHT | Director10% Owner | Nov 21 '24 | Sell | $3.73 | 551,802 | $2,058,221.46 | 632,456 |
Latest Sight Sciences Inc. News
SGHT Breaking Stock News: Dive into SGHT Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
MT Newswires
14 days ago
Sight Sciences Reports Positive OMNI Surgical System Data From 36-Month Study
GlobeNewswire
15 days ago
Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma
MT Newswires
a month ago
Sight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications
GlobeNewswire
a month ago
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options
TipRanks
a month ago
Sight Sciences initiated with a Buy at UBS
MT Newswires
2 months ago
UBS Initiates Sight Sciences at Buy With $5.50 Price Target
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 12/06/2024
Compare SGHT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SGHT Sight Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.